About Us
Pluristyx Inc. accelerates the development of revolutionary therapeutics to deliver, Tomorrow’s Cell Therapies, Today®.
At Pluristyx, we are dedicated to assisting our clients in the development of revolutionary cellular therapeutics. We offer a portfolio of induced Pluripotent Stem Cell (iPSC) products that are available in both research and clinical grade, as well as services that are widely applicable to numerous allogenic cellular therapies. At Pluristyx, we provide end-to-end support for early product development. About us we are committed to lowering the barrier to entry, providing a swift translation to clinic, and ensure the best path to commercialization for the next generation of iPSC-derived treatments.
About Us - Our Mission
Our mission is to revolutionize regenerative medicine. Pluristyx develops innovative solutions that empower breakthroughs in stem cell therapies, offering the potential to effectively treat diseases. As an early-stage, privately held biotechnology firm, we strive to advance cutting-edge techniques and technologies into the clinic.
Our service offering, the panCELLa Platform, represents a remarkable step in stem cell research, offering enhanced freedom to operate and unparalleled product development at a significantly accelerated timeline.
Our Offering
Our extensive portfolio of offerings equips clients with the ability to make impactful contributions and take active steps in combating previously incurable diseases. From initial concept through the evaluation of research grade materials to the development of a clinically compliant product, we walk alongside our partners to ensure a supportive and innovative environment that enhances therapeutic development and accelerates commercial transition.
We manufacture our cells to the highest industry standards and are dedicated to maximizing the impact on patients’ lives.
Our Portfolio
Pluristyx is armed with exclusive, worldwide licenses to cutting-edge techniques and technologies that set us apart in the industry. Our FailSafe® safety switch and induced Allogeneic Cell Tolerance, iACT Stealth Cells™, immune evasion technologies both alleviate the safety concerns inherent in cell-based living therapies.
Our innovative technologies raise the bar for safe, universal, cost-effective, “off-the-shelf” therapeutic cellular products for patients in need.
About Us - Our Mission
Our mission is to revolutionize regenerative medicine. Pluristyx develops innovative solutions that empower breakthroughs in stem cell therapies, offering the potential to effectively treat diseases. As an early-stage, privately held biotechnology firm, we strive to advance cutting-edge techniques and technologies into the clinic.
Our service offering, the panCELLa Platform, represents a remarkable step in stem cell research, offering enhanced freedom to operate and unparalleled product development at a significantly accelerated timeline.
Our Offering
Our extensive portfolio of offerings equips clients with the ability to make impactful contributions and take active steps in combating previously incurable diseases. From initial concept through the evaluation of research grade materials to the development of a clinically compliant product, we walk alongside our partners to ensure a supportive and innovative environment that enhances therapeutic development and accelerates commercial transition.
We manufacture our cells to the highest industry standards and are dedicated to maximizing the impact on patients’ lives.
Our Portfolio
Pluristyx is armed with exclusive, worldwide licenses to cutting-edge techniques and technologies that set us apart in the industry. Our FailSafe® safety switch and induced Allogeneic Cell Tolerance, iACT Stealth Cells™, immune evasion technologies both alleviate the safety concerns inherent in cell-based living therapies.
Our innovative technologies raise the bar for safe, universal, cost-effective, “off-the-shelf” therapeutic cellular products for patients in need.
About Us - Our Mission
Our mission is to revolutionize regenerative medicine. Pluristyx develops innovative solutions that empower breakthroughs in stem cell therapies, offering the potential to effectively treat diseases. As an early-stage, privately held biotechnology firm, we strive to advance cutting-edge techniques and technologies into the clinic.
Our service offering, the panCELLa Platform, represents a remarkable step in stem cell research, offering enhanced freedom to operate and unparalleled product development at a significantly accelerated timeline.
Our Offering
Our extensive portfolio of offerings equips clients with the ability to make impactful contributions and take active steps in combating previously incurable diseases. From initial concept through the evaluation of research grade materials to the development of a clinically compliant product, we walk alongside our partners to ensure a supportive and innovative environment that enhances therapeutic development and accelerates commercial transition.
We manufacture our cells to the highest industry standards and are dedicated to maximizing the impact on patients’ lives.
Our Portfolio
Pluristyx is armed with exclusive, worldwide licenses to cutting-edge techniques and technologies that set us apart in the industry. Our FailSafe® safety switch and induced Allogeneic Cell Tolerance, iACT Stealth Cells™, immune evasion technologies both alleviate the safety concerns inherent in cell-based living therapies.
Our innovative technologies raise the bar for safe, universal, cost-effective, “off-the-shelf” therapeutic cellular products for patients in need.
With over fifty years of collective executive expertise, Pluristyx is backed by a wealth of knowledge in stem cells and gene engineering. Operating from locations in Seattle, USA and Toronto, Canada our world-class teams collaborate seamlessly across our sites to consistently deliver exceptional results. Through these locations we cater to the needs of our international clientele in North America, Europe, and Asia, providing comprehensive assistance and solutions across borders and time zones.
About Us
Innovators
Our commitment to continuous Research and Development underscores our pledge to innovate, and enables us to discover solutions for tomorrow’s challenges, today. We are motivated by a vision to transform concepts into concrete outcomes and strive to achieve transformative results that will have a positive societal impact.
Client Centric
We thrive in our collaboration with clients to solve complex challenges. Our priority is to enable success by providing rapid and expert support at every stage of the research and therapeutic product development process.
Experts
Pluristyx was founded by industry experts and is home to seasoned professionals in the fields of stem cell biology, developmental genetics, gene engineering, and cell therapy. Passion drives our team's work as we tackle challenges with creative solutions.
Synonymous with Quality
Our GMP and non-GMP iPSC lines are developed and manufactured to the highest industry standards with the sole purpose of accelerating clinical translation. We stand by our offerings with our Try-Before-You-Buy model, enabling clients to evaluate our edited and non-edited cellular products before committing to a license.
Able to Streamline the Process
Our exclusive access to patented technologies provides our partners with the freedom to operate, develop, and innovate, eliminating steps from the process and reducing their timeline. We simplify the cell therapy development process by conveniently offering products and services to our clients through a single partnership.